BLAU3
Blau Farmacêutica S.A.Report (Preview)
Detailed and complete analysis about this companyAccess full B3 reports
Full analysis — BLAU3 is available only for Premium subscribers.
With Premium you have access to detailed reports of all companies, with valuation and fair price.
Price Chart
Data provided by TradingView
Loading chart...
Analyst Recommendations
Valuation Multiples
Margins & Profitability
Growth
Corporate Risk
Dividends
Moving Averages
Average Volume
Dividend History (12m)
Price Evolution (12m)
Seasonality Study
Historical monthly performance of the asset over the last 6 years. Helps identify seasonal behavior patterns.
Avg Return (%)
High Frequency (%)
Best Month
2nd Best
High Frequency
High Frequency
Balance Sheet
| Period | Total Assets | Liabilities | Total Equity |
|---|---|---|---|
| 2025 | R$3.64B | R$1.38B | R$2.27B |
| 2024 | R$3.41B | R$1.26B | R$2.16B |
| 2023 | R$3.05B | R$1.06B | R$2B |
| 2022 | R$2.5B | R$681M | R$1.82B |
MyHub Discussion (0)
About the Company
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics products. Blau Farmacêutica S.A. was incorporated in 1987 and is headquartered in Cotia, Brazil.
Market Data
- Market CapR$2.07B
- Min 52sMax 52sR$8.28R$14.50
- Average Volume252.2K